Saltar al contenido principal

Lamentablemente no somos totalmente compatibles con su navegador. Si tiene la opción, actualice a una versión más reciente o utilice Mozilla Firefox, Microsoft Edge, Google Chrome o Safari 14 o posterior. Si no puede y necesita ayuda, envíenos sus comentarios.

Agradeceríamos sus comentarios sobre esta nueva experiencia.Díganos qué piensase abre en una nueva pestaña/ventana

Elsevier
Publique con nosotros
Press release

Novel Rat Model Paves the Way to Advance COPD-Associated Cor Pulmonale Research

30 de abril de 2025

A study published in The American Journal of Pathology details the ability of the rat model to unravel the complex interactions between lung and heart pathology

Researchers have developed a novel rat model that closely replicates the pathological features and physiological changes associated with human chronic obstructive pulmonary disease (COPD)-associated cor pulmonale. This model exhibits key characteristics, including chronic lung inflammation, pulmonary hypertension, and right ventricular hypertrophy. The new studyopens in new tab/window in The American Journal of Pathologyopens in new tab/window, published by Elsevier, details the potential for the model to unravel the complex interactions between lung and heart pathology and improve patient outcomes.

COPD is a common chronic respiratory disease characterized by persistent respiratory symptoms and airflow limitation. The World Health Organization has ranked COPD as the third leading cause of mortality globally, with approximately 3.23 million deaths attributed to the disease in 2019. Approximately 6% of COPD patients develop cor pulmonale each year, which is a dysfunction of the right ventricle resulting from pulmonary disease and significantly deteriorates the prognosis of COPD. Cor pulmonale not only increases mortality among patients but also imposes a substantial economic burden on society. However, progress in related therapeutic research has been hampered by the lack of animal models that accurately simulate the complex interactions between COPD and cor pulmonale.

Lead investigator Tao Wang, MD, PhD, State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Guangzhou Medical University, China, says, "The prognosis for individuals with COPD complicated by cor pulmonale is generally poor, and the existing treatment options are inadequate. To address the urgent need for a more accurate animal model of COPD-associated cor pulmonale, we were dedicated to developing a novel rat model to better emulate the human disease, providing valuable tools for future research and therapeutic development."

The researchers employed a comprehensive approach to developing and characterizing a novel rat model of COPD-associated cor pulmonale. The disease state was induced by combining chronic cigarette smoke exposure with left pulmonary artery ligation, followed by rigorous physiological, histological, and molecular analyses. The results demonstrated that this model recapitulated the pulmonary dysfunction, emphysema, and inflammatory infiltration characteristic of COPD. In addition, it also reproduced key features of cor pulmonale, including right ventricular hypertrophy, fibrosis, capillary rarefaction, and hemodynamic changes associated with pulmonary hypertension. Also, the investigators identified that pathways involving inflammation and oxidative stress may play significant roles in disease progression, highlighting their potential as therapeutic targets.

Co-lead investigator Lingdan Chen, MD, State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Guangzhou Medical University, China, notes, "The development of this novel rat model represents a significant step forward in our ability to study COPD-associated cor pulmonale. By elucidating the underlying mechanisms of the disease and developing more effective therapeutic strategies, it provides an essential tool for overcoming the therapeutic challenges posed by this condition."

This model is expected to facilitate the discovery of novel molecular insights and the identification of innovative therapeutic targets.

Co-investigators Zhuoji Ma, MSc, State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, Department of Pulmonary and Critical Care Medicine, the First Affiliated Hospital of Guangzhou Medical University, China, and Suiyang Tong, PhD, Department of Cardiology, Suizhou Hospital, Hubei University of Medicine, China, conclude, "We are excited about the potential of this model to accelerate the discovery of new therapeutic strategies, which are desperately needed for patients with COPD-associated cor pulmonale."

Notes for editors

The article is “Development and Characterization of a Novel Rat Model for Emulating Chronic Obstructive Pulmonary Disease—Associated Cor Pulmonale,” by Zhuoji Ma, Suiyang Tong, Yuhang Huang, Neng Wang, Guanjin Chen, Qianwen Bai, Jia Deng, Liang Zhou, Qiao Luo, Jian Wang, Wenju Lu, Lingdan Chen, and Tao Wang (https://doi-org.ucc.idm.oclc.org/10.1016/j.ajpath.2025.01.003opens in new tab/window). It appears in The American Journal of Pathology, volume 195, issue 5 (May 2025), published by Elsevier.

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(25)00034-3/fulltextopens in new tab/window.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window to request a PDF of the article or more information. To reach the study’s authors, contact Tao Wang, MD, PhD, at [email protected]opens in new tab/window.

This work was supported by grants from the National Natural Science Foundation of China (82270053 and 82241024), Guangdong Outstanding Young Scientist Funding (2021B1515020006), the Science and Technology Program of Guangzhou, China (SL2024A04J01572 and SL2023A03J01309), R&D Program of Guangzhou National Laboratory (grant GZNL2023A02013), and Hubei Provincial Key Research and Development Program (Health Care Field Supporting Local Special Projects; 2022BCE053).

About The American Journal of Pathology

The American Journal of Pathologyopens in new tab/window, official journal of the American Society for Investigative Pathologyopens in new tab/window, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. ajp.amjpathol.orgopens in new tab/window

Acerca de Elsevier

Elsevier es líder global en información avanzada y soporte para la toma de decisiones. Durante más de un siglo, ha ayudado a avanzar la ciencia y la salud para promover el progreso humano. Apoya a comunidades de investigación académicas y corporativas, médicos, enfermeras, futuros profesionales de la salud y educadores en 170 países, proporcionándoles conocimientos críticos y soluciones innovadoras que combinan contenido científico y médico confiable con tecnologías de IA de vanguardia. Elsevier promueve la inclusión y la sostenibilidad incorporando estos valores en sus productos y cultura. La Elsevier Foundation respalda investigaciones y asociaciones de salud alrededor del mundo.

Elsevier forma parte de RELX, proveedor global de herramientas de análisis y decisión basadas en información para clientes profesionales y de negocios. Para más información, visite www.elsevier.com y síganos en redes sociales: @ElsevierConnect.

Contacto

EL

Eileen Leahy

Elsevier

+1 732 406 1313

Correo electrónico Eileen Leahy

CCP

Chhavi Chauhan, PhD

Director of Scientific Outreach

The American Journal of Pathology

+1 240 283 9724

Correo electrónico Chhavi Chauhan, PhD